Menu
Search
|

Menu

Close
X

Alimera Sciences Inc ALIM.OQ (NASDAQ Stock Exchange Global Market)

0.41 USD
+0.01 (+3.80%)
As of Sep 13
Previous Close 0.40
Open 0.43
Volume 68,604
3m Avg Volume 43,934
Today’s High 0.43
Today’s Low 0.39
52 Week High 1.20
52 Week Low 0.32
Shares Outstanding (mil) 71.00
Market Capitalization (mil) 63.53
Forward P/E 2.38
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
13
FY18
47
FY17
36
FY16
34
EPS (USD)
FY19
-0.039
FY18
0.319
FY17
-0.328
FY16
-0.656
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
2.38
33.85
Price to Sales (TTM)
vs sector
1.27
7.90
Price to Book (MRQ)
vs sector
--
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
--
17.64
LT Debt to Equity (MRQ)
vs sector
--
12.61
Return on Investment (TTM)
vs sector
-29.58
12.69
Return on Equity (TTM)
vs sector
--
17.13

EXECUTIVE LEADERSHIP

C. Daniel Myers
Non-Executive Chairman of the Board, Since 2019
Salary: $519,120.00
Bonus: --
Richard Eiswirth
President, Chief Executive Officer, Since 2019
Salary: $425,000.00
Bonus: --
Phil Jones
Chief Financial Officer, Since 2019
Salary: --
Bonus: --
David Holland
Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets, Since 2018
Salary: $344,000.00
Bonus: $6,880.00
Philip Ashman
Senior Vice President, European Managing Director, Since 2013
Salary: $310,000.00
Bonus: $6,085.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

6120 Windward Pkwy Ste 290
ALPHARETTA   GA   30005-8897

Phone: +1678.9905740

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

SPONSORED STORIES